New: NCI-funded clinical trial search
Mednet Logo
CommunityGeriatric Medicine

In your clinical practice, how are you approaching consideration of limbic-predominant age-related TDP-43 encephalopathy (LATE) in the differential diagnosis for older adults previously thought to have Alzheimer's disease?

Wolk et al., PMID 39807681
Community PollStarted

How often are you considering limbic-predominant age-related TDP-43 encephalopathy (LATE) in the differential diagnosis for older adults with cognitive changes?

23 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers
Mednet MemberInvited Expert
Geriatric Medicine · Wake Forest University School of Medicine
Answered on

At the moment, I am not finding that this diagnosis is extremely helpful. In general, LATE looks for all the world like AD at the time of diagnosis in the oldest patients, but it doesn't progress like we expect it to. LATE, by itself, seems to be a much more slowly progressive disease. So I find myself looking at a patient in their mid 80's, who I diagnosed with AD a few years earlier, who is not really declining cognitively or functionally as I expected them to, and say to patients and families, "Well, maybe this is not actually AD, but a more recently recognized neurodegenerative dementia called LATE".

Until it can be diagnosed more accurately with biomarkers, and/or there are specific therapies for it, I think that's about the best that ...

Join for free or sign in to see the full answer

Mednet Member
Geriatric Medicine · Beaumont Hospital, Royal Oak
Answered on

I consider LATE in almost all older patients in late life (>85) when they present to me with cognitive changes.

I agree, biomarkers are necessary for a more precise diagnosis. But clinical history of slow progression and reasonably well-maintained functional status clues towards LATE rather than AD. The biggest advantage in considering this in the differential is to discuss the benign prognosis compared to AD, alleviate fears for the patient and family, and to approach amyloid imaging/MAb therapy more cautiously.

Join for free or sign in to see the full answer